{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:47:55Z","timestamp":1792673275055,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"DOI":"10.1007\/s10147-026-03218-5","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:21:17Z","timestamp":1792671677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical benefit and economic value of fosnetupitant versus aprepitant in carboplatin-Based chemotherapy: a real-world study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-9822","authenticated-orcid":false,"given":"Hiroshi","family":"Inano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Niizuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanata","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Usami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozue","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Shono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Otori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"3218_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-017-3857-7","volume":"26","author":"K Jordan","year":"2018","unstructured":"Jordan K, Bl\u00e4ttermann L, Hinke A et al (2018) Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?\u2014a systematic review and meta-analysis. Support Care Cancer 26:21\u201332. https:\/\/doi.org\/10.1007\/s00520-017-3857-7","journal-title":"Support Care Cancer"},{"key":"3218_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M et al (2024) 2023 Japan Society of Clinical Oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol 29:873\u2013888. https:\/\/doi.org\/10.1007\/s10147-024-02535-x","journal-title":"Int J Clin Oncol"},{"key":"3218_CR3","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00520-013-2106-y","volume":"22","author":"JD Lundberg","year":"2014","unstructured":"Lundberg JD, Crawford BS, Phillips G et al (2014) Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. Support Care Cancer 22:1461\u20131466. https:\/\/doi.org\/10.1007\/s00520-013-2106-y","journal-title":"Support Care Cancer"},{"key":"3218_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1248\/bpb.b23-00819","volume":"47","author":"H Inano","year":"2024","unstructured":"Inano H, Morimoto Y, Kitagawa K et al (2024) Comparing the efficacy of fosnetupitant, an NK1 receptor antagonist in CDDP-based regimens, with that of fosaprepitant and aprepitant: a retrospective observational study. Biol Pharm Bull 47:692\u2013697. https:\/\/doi.org\/10.1248\/bpb.b23-00819","journal-title":"Biol Pharm Bull"},{"key":"3218_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10147-025-02940-w","volume":"31","author":"H Inano","year":"2026","unstructured":"Inano H, Morimoto Y, Kawamura A et al (2026) Sustained antiemetic efficacy of fosnetupitant versus aprepitant in carboplatin-based chemotherapy: a retrospective observational study. Int J Clin Oncol 31:301\u2013309. https:\/\/doi.org\/10.1007\/s10147-025-02940-w","journal-title":"Int J Clin Oncol"},{"key":"3218_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00520-025-09210-5","volume":"33","author":"H Inano","year":"2025","unstructured":"Inano H, Morimoto Y, Kitagawa K et al (2025) Cost-effectiveness analysis of fosnetupitant in patients receiving cisplatin in Japan: analysis based on real-world data. Support Care Cancer 33:149. https:\/\/doi.org\/10.1007\/s00520-025-09210-5","journal-title":"Support Care Cancer"},{"key":"3218_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"DN Lakdawalla","year":"2018","unstructured":"Lakdawalla DN, Doshi JA, Garrison LP Jr et al (2018) Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force report [3]. Value Health 21:131\u2013139. https:\/\/doi.org\/10.1016\/j.jval.2017.12.007","journal-title":"Value Health"},{"key":"3218_CR8","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMp1011024","volume":"363","author":"ME Porter","year":"2010","unstructured":"Porter ME (2010) What is value in health care? N Engl J Med 363:2477\u20132481. https:\/\/doi.org\/10.1056\/NEJMp1011024","journal-title":"N Engl J Med"},{"key":"3218_CR9","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P et al (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478. https:\/\/doi.org\/10.1200\/JCO.2006.05.6382","journal-title":"J Clin Oncol"},{"key":"3218_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-1979-x","volume":"5","author":"T Tachi","year":"2016","unstructured":"Tachi T, Teramachi H, Tanaka K et al (2016) The impact of side effects from outpatient chemotherapy on presenteeism in breast cancer patients: a prospective analysis. Springerplus 5:327. https:\/\/doi.org\/10.1186\/s40064-016-1979-x","journal-title":"Springerplus"},{"key":"3218_CR11","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/cncr.22823","volume":"110","author":"YC Tina Shih","year":"2007","unstructured":"Tina Shih YC, Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110:678\u2013685. https:\/\/doi.org\/10.1002\/cncr.22823","journal-title":"Cancer"},{"key":"3218_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08119-1","volume":"31","author":"L Schwartzberg","year":"2023","unstructured":"Schwartzberg L, Navari RM, Ruddy KJ et al (2023) Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis. Support Care Cancer 31:654. https:\/\/doi.org\/10.1007\/s00520-023-08119-1","journal-title":"Support Care Cancer"},{"key":"3218_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/CMAR.S44539","volume":"5","author":"S Humphreys","year":"2013","unstructured":"Humphreys S, Pellissier J, Jones A (2013) Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. Cancer Manag Res 5:215\u2013224. https:\/\/doi.org\/10.2147\/CMAR.S44539","journal-title":"Cancer Manag Res"},{"key":"3218_CR15","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1007\/s00520-019-04672-w","volume":"27","author":"I Tsukiyama","year":"2019","unstructured":"Tsukiyama I, Ando M, Tsukiyama S et al (2019) Cost-utility analysis of aprepitant for patients who truly need it in Japan. Support Care Cancer 27:3749\u20133758. https:\/\/doi.org\/10.1007\/s00520-019-04672-w","journal-title":"Support Care Cancer"},{"key":"3218_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, Bodurka DC, Weaver CB et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219\u2013227. https:\/\/doi.org\/10.1007\/s00520-004-0710-6","journal-title":"Support Care Cancer"},{"key":"3218_CR17","first-page":"225","volume":"69","author":"K Yamasaki","year":"2021","unstructured":"Yamasaki K, Ozawa K, Yagi R et al (2021) Factors influencing workplace conditions of cancer patients who may be absent from work due to outpatient chemotherapy (in Japanese). J Jpn Occup Med Traumatol 69:225\u2013230","journal-title":"J Jpn Occup Med Traumatol"},{"key":"3218_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hec.1481","volume":"19","author":"T Shiroiwa","year":"2010","unstructured":"Shiroiwa T, Sung YK, Fukuda T et al (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 19:422\u2013437. https:\/\/doi.org\/10.1002\/hec.1481","journal-title":"Health Econ"},{"key":"3218_CR19","volume-title":"Overview of national medical expenditure in fiscal year 2023","author":"Ministry of Health, Labour and Welfare, Japan","year":"2025","unstructured":"Ministry of Health, Labour and Welfare, Japan (2025) Overview of national medical expenditure in fiscal year 2023. Ministry of Health, Labour and Welfare, Tokyo"},{"key":"3218_CR20","volume-title":"Health at a glance 2023: Japan","author":"Organization for Economic Co-operation and Development","year":"2023","unstructured":"Organization for Economic Co-operation and Development (2023) Health at a glance 2023: Japan. OECD Publishing, Paris"},{"key":"3218_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015645","volume":"7","author":"U Restelli","year":"2017","unstructured":"Restelli U, Saibene G, Nardulli P et al (2017) Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open 7:e015645. https:\/\/doi.org\/10.1136\/bmjopen-2016-015645","journal-title":"BMJ Open"},{"key":"3218_CR22","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212298","volume":"6","author":"H Cawston","year":"2017","unstructured":"Cawston H, Bourhis F, Eriksson J et al (2017) NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context 6:212298. https:\/\/doi.org\/10.7573\/dic.212298","journal-title":"Drugs Context"},{"key":"3218_CR23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00520-019-04824-y","volume":"28","author":"M Botteman","year":"2020","unstructured":"Botteman M, Nickel K, Corman S et al (2020) Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Support Care Cancer 28:857\u2013866. https:\/\/doi.org\/10.1007\/s00520-019-04824-y","journal-title":"Support Care Cancer"},{"key":"3218_CR24","doi-asserted-by":"publisher","first-page":"9307","DOI":"10.1007\/s00520-022-07339-1","volume":"30","author":"J Nilsson","year":"2022","unstructured":"Nilsson J, Piovesana V, Turini M et al (2022) Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective. Support Care Cancer 30:9307\u20139315. https:\/\/doi.org\/10.1007\/s00520-022-07339-1","journal-title":"Support Care Cancer"},{"key":"3218_CR25","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1111\/cas.13736","volume":"109","author":"I Tsukiyama","year":"2018","unstructured":"Tsukiyama I, Hasegawa S, Ikeda Y et al (2018) Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy. Cancer Sci 109:2881\u20132888. https:\/\/doi.org\/10.1111\/cas.13736","journal-title":"Cancer Sci"},{"key":"3218_CR26","first-page":"95","volume":"42","author":"N Nakagawa","year":"2018","unstructured":"Nakagawa N, Watanabe Y, Kikuchi M et al (2018) A cost-effectiveness analysis of neurokinin 1 receptor antagonists for the FEC100 regimen in breast cancer (in Japanese). J Drug Interact Res 42:95\u2013102","journal-title":"J Drug Interact Res"},{"key":"3218_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.clinthera.2019.03.011","volume":"41","author":"M Kashiwa","year":"2019","unstructured":"Kashiwa M, Matsushita R (2019) Comparative cost-utility analysis between aprepitant- and fosaprepitant-containing regimens to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan. Clin Ther 41:929\u2013942. https:\/\/doi.org\/10.1016\/j.clinthera.2019.03.011","journal-title":"Clin Ther"},{"key":"3218_CR28","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1007\/s12325-023-02537-7","volume":"40","author":"RM Navari","year":"2023","unstructured":"Navari RM, Nelson WW, Shoaib S et al (2023) Real-world treatment outcomes, healthcare resource use, and costs associated with antiemetics among cancer patients on cisplatin-based chemotherapy. Adv Ther 40:3217\u20133226. https:\/\/doi.org\/10.1007\/s12325-023-02537-7","journal-title":"Adv Ther"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03218-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03218-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03218-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:21:19Z","timestamp":1792671679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03218-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":27,"alternative-id":["3218"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03218-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Kitasato University Hospital (Approval No. B24-048) and was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given that this was a retrospective study and that all data were collected retrospectively from electronic medical records, the requirement for informed consent was waived by the Ethics Committee of Kitasato University Hospital. However, we also offered participants the opportunity to opt out of using their data.","order":3,"name":"Ethics","label":"Consent to participate and publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Generative AI (ChatGPT, OpenAI) was used to assist with language editing, sentence restructuring, and the refinement of academic expressions. The authors reviewed, verified, and took full responsibility for all content and interpretations presented in this manuscript.","order":4,"name":"Ethics","label":"AI use","group":{"name":"EthicsHeading","label":"Declarations"}}]}}